Blood & Marrow Transplantation
Message From the Chief
Welcome to the Division of Blood and Marrow Transplantation. We are very proud of the outstanding compassionate care that we provide our patients along with conducting state of the art basic and translational science on stem cell biology, cellular immunology and transplantation biology.
The BMT program at Stanford performs autologous and allogeneic transplantations for over 300 patients each year. The program has been very successful with a history of limited morbidity rates and acute mortality that is well below most published reports.
Make a Gift
Our cutting-edge research is developing novel immunotherapy for cancer. Support the BMT Division by making a donation to our research fund.
In the News
One way to bring the powerful cellular immunity and antibody directed targeting together is to construct the chimeric antigen receptor (CAR) T-cells. In this strategy, the patient’s own T-cells are genetically engineered to produce a hybrid molecule (the CAR) on these killing cells.
In order to monitor disease after a curative treatment such as allogeneic transplant, pioneer works from Drs. David Miklos and Wen-Kai Weng have established the utility of high-throughput sequencing (HTS) of either B-cell receptor (BCR) or T-cell receptor (TCR) in monitoring minimal residual disease (MRD).
The development of normal lymphocytes is a well-orchestrated process, that begins in the bone marrow. This process involves a functional antigen receptor (B-cell receptor or T-cell receptor) and a dozen of intermediators, including adaptor proteins and kinases that form a network of signaling pathways inside the cells.
DO YOU KNOW?
More than 360 adults have received bone marrow or stem cell transplants at Stanford every year.